HOME >> MEDICINE >> NEWS
Cordis Cardiology Introduces The MINI Crown Stent

FDA Clears Coronary Artery Stent Specifically Engineered For Smaller Vessels

MIAMI, FL (April 19, 1999) -- Cordis Cardiology today announced U.S. Food and Drug Administration approval to market its new MINI Crown stent (the MINI) specifically engineered for smaller coronary vessels (lumen diameters from 3.25 mm to as small as 2.25 mm). Cordis Cardiology is a unit of Cordis Corporation, a Johnson & Johnson company.

According to David O. Williams, M.D., Division of Cardiology, Rhode Island Hospital, Providence, RI, who served as principal investigator in the clinical trial of the MINI, many physicians view smaller vessel stenting as the next frontier in interventional cardiology.

"There's no question that there is high physician demand for a quality smaller vessel stent," said Dr. Williams. "I find the MINI to be the best choice for stenting smaller vessels. It offers many unique advantages, such as one-step deployment, a low-profile delivery system, minimal balloon overhang, and precise balloon sizing at higher pressures -- all of which, in my opinion, make the procedure safe."

Jesse Penn, president, Cordis Cardiology, said the company initially will offer the MINI in 11 mm and 15 mm lengths and diameters ranging from 3.25 mm to 2.25 mm in quarter sizes. Penn described the MINI as the stent that enables physicians to "go smaller safely," predicting that it will soon become the "gold standard" for smaller vessel stenting.

Penn also explained that the MINI and the DynastyTM; delivery system have been carefully designed to respond to the need for a stenting system that offers easy deliverability in patients with small, tight lesions while minimizing the risks of edge dissection and stent embolization.

"We're addressing the issue of edge dissection by 1) using the new non-compliant DURAMAX balloon material to control expansion and 2) closely matching balloon and stent
'"/>

Contact: Robert Murphy
rmurphy@intac.com
908-273-1400
D. J. Storch & Associates Inc.
18-Apr-1999


Page: 1 2 3

Related medicine news :

1. The European Society of Cardiology launches Women at Heart
2. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology
3. Cardiology losing out as women turned off by family unfriendly specialty
4. Media invitation - European Society of Cardiology Congress 2004
5. Cedars-Sinai researchers to present findings at Amerian College of Cardiology Scientific Meeting
6. American Heart Association and American College of Cardiology update guidelines for treatment of heart attack
7. Stents and going with the flow
8. Stents combined with clot-busting drugs effective in limiting impact of deadly form of stroke
9. Stent or bypass surgery for coronary artery disease?
10. Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
11. American Heart Association Comment: Nonsurgical Reconstruction Of Thoracic Aortic Dissection By Stent-Graft Placement

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cordis Cardiology Introduces The MINI Crown Stent

(Date:5/20/2013)... NL, 20 May 2013 While Huntington,s disease ... anticipates that new disease-modifying therapies in development may ... of HD research depends upon the identification of ... evaluate therapies, and these biomarkers may eventually be ... could be especially helpful to monitor changes during ...
(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest ... it has earned a Commendable Accreditation status from ... Health is a wholly owned subsidiary of Horizon Blue ... Health Plan Accreditation is a nationally recognized program that ... plans provide to their members. Health Plan Accreditation performance ...
(Date:5/20/2013)... May 20, 2013 The American Society ... for Bright Pink®, the organization that empowers young women to ... end of 2012. Thanks to its members, ASCP raised more ... is involved in Relay for Life at the local level. ... he decided to donate. “I was made aware of the ...
(Date:5/20/2013)... The nationwide law firm of Bernstein Liebhard LLP ... imaging (MRI) can be used to predict metal-on-metal hip ... experiencing symptoms. According to an article published on May ... MRI detected synovitis (tissue damage) in 68% of asymptomatic patients ... causes, the detection rate was 75%, while MRIs were able ...
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- Boys who are ... likely to become obese adults as those who didn,t ... 30-year study shows. Researchers found that men with ... (BMI) and obesity, even if they no longer had ... well-off or poor, they tended toward obesity. "The ...
Breaking Medicine News(10 mins):Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3
(Date:5/20/2013)... YORK , May 20, 2013  Echo Pharma ... 2.5 of the Irish Takeover Rules (the "Announcement"), a ... plc (NYSE: ELN ) to $12.50 per ... cash confirmed and not conditional on due diligence.  The ... Royalty Pharma has reserved the right to waive down ...
(Date:5/20/2013)... , May 20, 2013  Atlantic Pharmaceuticals, Inc., ... is commercializing a unique technology to deter prescription ... President, Anthony Soscia , has ... Atlanta Business Chronicle ,s Health-Care Heroes Awards. The ... Business Chronicle to honor individuals and organizations demonstrating ...
(Date:5/20/2013)... May 20, 2013  Rhythm announced today the presentation ... higher prevalence of gastroparesis symptoms among diabetic patients in ... is high among patients with both type 1 and ... among those with the more common type 2 disease. ... MD, PhD, Associate Professor of Medicine at Harvard Medical ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
Cached News: